Stock EXEL EXELIXIS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Exelixis, Inc.

Equities

EXEL

US30161Q1040

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-20 pm EDT 		5-day change 1st Jan Change
21.06 USD +0.72% Intraday chart for Exelixis, Inc. -0.99% -12.21%
May. 20 Exelixis Settles Cabometyx Patent Litigation with Cipla MT
May. 14 Transcript : Exelixis, Inc. Presents at 2024 RBC Capital Markets Global Healthcare Conference, May-14-2024 02:35 PM

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 5,354 6,227 5,784 5,174 7,460 6,135 - -
Enterprise Value (EV) 1 4,502 5,020 4,317 3,865 6,465 5,012 4,462 3,866
P/E ratio 17.3 x 57.3 x 25.4 x 28.6 x 36.9 x 18.7 x 14.4 x 11.2 x
Yield - - - - - - - -
Capitalization / Revenue 5.53 x 6.31 x 4.03 x 3.21 x 4.08 x 3.27 x 2.98 x 2.69 x
EV / Revenue 4.65 x 5.08 x 3.01 x 2.4 x 3.53 x 2.67 x 2.16 x 1.7 x
EV / EBITDA 11.9 x 42.1 x 14.4 x 17.4 x 32.9 x 10.8 x 7.84 x 5.63 x
EV / FCF 8.76 x 28.1 x 12.8 x 17.2 x 22.1 x 13.4 x 10.7 x 8.05 x
FCF Yield 11.4% 3.56% 7.8% 5.8% 4.53% 7.49% 9.31% 12.4%
Price to Book 3.19 x 3.4 x 2.64 x 2.09 x 3.21 x 2.49 x 1.98 x 1.63 x
Nbr of stocks (in thousands) 303,846 310,244 316,397 322,561 310,974 291,293 - -
Reference price 2 17.62 20.07 18.28 16.04 23.99 21.06 21.06 21.06
Announcement Date 2/25/20 2/10/21 2/17/22 2/7/23 2/6/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 967.8 987.5 1,435 1,611 1,830 1,877 2,061 2,278
EBITDA 1 377.8 119.2 300.3 222.4 196.6 462.2 569.5 686.4
EBIT 1 369.5 110.1 286.7 201.5 170.9 360.8 488.6 620.3
Operating Margin 38.18% 11.14% 19.98% 12.51% 9.34% 19.22% 23.7% 27.23%
Earnings before Tax (EBT) 1 398.1 130.8 294.2 234.4 257.5 426.9 582.5 736.2
Net income 1 321 111.8 231.1 182.3 207.8 342.5 444.4 571
Net margin 33.17% 11.32% 16.1% 11.31% 11.35% 18.24% 21.56% 25.06%
EPS 2 1.020 0.3500 0.7200 0.5600 0.6500 1.127 1.465 1.882
Free Cash Flow 1 514.1 178.6 336.6 224.2 292.9 375.4 415.5 480.3
FCF margin 53.12% 18.09% 23.46% 13.91% 16% 20% 20.16% 21.08%
FCF Conversion (EBITDA) 136.08% 149.86% 112.08% 100.81% 148.96% 81.22% 72.97% 69.98%
FCF Conversion (Net income) 160.16% 159.81% 145.67% 122.97% 140.95% 109.62% 93.51% 84.12%
Dividend per Share 2 - - - - - - - -
Announcement Date 2/25/20 2/10/21 2/17/22 2/7/23 2/6/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 451.1 356 419.4 411.7 423.9 408.8 469.8 471.9 479.7 425.2 466.2 480.4 496.2 461.5 497.8
EBITDA 1 - - - 88.28 -42.13 - - - 88.31 - 107.9 82.13 119.8 - -
EBIT 1 116.6 83.24 83.71 82.61 -48.08 28.83 77.85 -17.58 81.79 29.46 98.38 102.6 113.7 71.07 102.5
Operating Margin 25.86% 23.38% 19.96% 20.06% -11.34% 7.05% 16.57% -3.73% 17.05% 6.93% 21.1% 21.37% 22.92% 15.4% 20.59%
Earnings before Tax (EBT) 1 118 85.23 88.51 92.04 -31.43 48.28 100.4 5.818 103 49.27 118.5 122.4 134.7 87.65 120
Net income 1 95.17 68.57 70.67 73.21 -30.17 40.03 81.18 1.041 85.52 37.32 93.23 97.95 103.3 69.59 95.39
Net margin 21.09% 19.26% 16.85% 17.78% -7.12% 9.79% 17.28% 0.22% 17.83% 8.78% 20% 20.39% 20.83% 15.08% 19.16%
EPS 2 0.2900 0.2100 0.2200 0.2300 -0.0900 0.1200 0.2500 - 0.2700 0.1200 0.3103 0.3304 0.3533 0.2825 0.3500
Dividend per Share - - - - - - - - - - - - - - -
Announcement Date 2/17/22 5/10/22 8/9/22 11/1/22 2/7/23 5/9/23 8/1/23 11/1/23 2/6/24 4/30/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 852 1,207 1,467 1,308 995 1,122 1,672 2,269
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 514 179 337 224 293 375 416 480
ROE (net income / shareholders' equity) 21.6% 10.8% 11.3% 7.76% 8.74% 16.3% 16.6% 17.4%
ROA (Net income/ Total Assets) 19.4% - 9.72% 6.41% 6.91% 11.2% 11% 12.6%
Assets 1 1,654 - 2,377 2,844 3,007 3,058 4,040 4,531
Book Value Per Share 2 5.530 5.910 6.930 7.680 7.480 8.470 10.60 12.90
Cash Flow per Share 2 1.670 0.6600 1.240 1.120 1.040 1.270 1.760 -
Capex 1 12.8 30.3 64.2 138 40.5 38.7 38.3 39.8
Capex / Sales 1.33% 3.07% 4.48% 8.59% 2.21% 2.06% 1.86% 1.75%
Announcement Date 2/25/20 2/10/21 2/17/22 2/7/23 2/6/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Exelixis, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
21.06 USD
Average target price
26.59 USD
Spread / Average Target
+26.26%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
EXELIXIS, INC. Stock Exelixis, Inc.
-12.21% 6.13B
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+9.58% 115B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+12.41% 107B
BIONTECH SE Stock BioNTech SE
-12.38% 22.31B
ARGENX SE Stock argenx SE
-3.20% 21.6B
BEIGENE, LTD. Stock BeiGene, Ltd.
-3.35% 18.23B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-38.57% 17.62B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+7.51% 14.26B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+35.67% 12.37B
LEGEND BIOTECH CORPORATION Stock Legend Biotech Corporation
-24.50% 8.28B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. EXEL Stock
  4. Financials Exelixis, Inc.
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW